ADC Therapeutics SA
ADCT
$3.70
-$0.26-6.57%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.85% | 6.35% | 15.73% | 10.49% | 1.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.85% | 6.35% | 15.73% | 10.49% | 1.84% |
| Cost of Revenue | -11.02% | -5.35% | 7.41% | -6.33% | -3.23% |
| Gross Profit | 115.81% | 42.64% | 20.20% | 52.13% | 19.48% |
| SG&A Expenses | -6.96% | -12.07% | -12.82% | -15.70% | -18.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.26% | -6.07% | -1.11% | -8.35% | -15.10% |
| Operating Income | 17.84% | 12.42% | 9.21% | 17.00% | 22.20% |
| Income Before Tax | 10.19% | 1.57% | 1.56% | 20.61% | 21.53% |
| Income Tax Expenses | 511.45% | -97.48% | -97.27% | -99.57% | -99.58% |
| Earnings from Continuing Operations | 9.64% | 21.31% | 20.92% | 34.07% | 34.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.64% | 21.31% | 20.92% | 34.07% | 34.25% |
| EBIT | 17.84% | 12.42% | 9.21% | 17.00% | 22.20% |
| EBITDA | 17.54% | 12.34% | 9.35% | 17.21% | 22.45% |
| EPS Basic | 27.55% | 39.57% | 38.41% | 47.48% | 43.56% |
| Normalized Basic EPS | 35.38% | 30.03% | 29.25% | 37.42% | 33.35% |
| EPS Diluted | 27.55% | 39.57% | 38.41% | 47.48% | 43.56% |
| Normalized Diluted EPS | 35.38% | 30.03% | 29.25% | 37.42% | 33.35% |
| Average Basic Shares Outstanding | 30.69% | 26.67% | 25.78% | 25.73% | 18.86% |
| Average Diluted Shares Outstanding | 30.69% | 26.67% | 25.78% | 25.73% | 18.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |